Back to top

Insight 5

Tekmira Pharmaceuticals is shifting focus after years of up-and-down development, planning to change its name and train its attention on hepatitis B.

The Canadian biotech will do business as Arbutus Biopharma come Aug. 6, a name change the company says will reflect the integration of OnCore BioPharma, which it acquired in January. Buying OnCore, a venture founded by veterans of Pharmasset, Tekmira got its hands on a pipeline of potential cures for hepatitis B, and the company now plans to build its future around those candidates and its own preclinical treatment for the virus

"Every science begins as philosophy and ends as art." Will Durant,